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Abstract
            Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is characterized 
by the patchy replacement of myocardium by fatty or fibrofatty tissue. These changes lead to 
structural abnormalities including right ventricular enlargement and wall motion abnormalities 
that can be detected by echocardiography, angiography, and cine MRI. ARVC/D is a genetically 
heterogeneous disorder, since it has been linked to several chromosomal loci. Myocarditis may 
also be a contributing etiological factor. Patients are typically diagnosed during adolescence or 
young adulthood. Presenting symptoms are generally related to ventricular arrhythmias. Concern 
for the risk of sudden cardiac death may lead to the implantation of an intracardiac defibrillator. 
An ongoing multicenter international registry should further our understanding of this disease.
Introduction
            Arhythmogenic right ventricular cardiomypathy/dysplasia (ARVC/D) is a disorder in 
which the right ventricular myocardium is interspersed with fatty or fibrofatty tissue. This 
pathological process principally affects the right ventricle, but in advanced cases can lead to 
biventricular   involvement.   Linkage   analysis   has   identified   several   loci   on   different 
chromosomes, indicating this disease is genetically heterogeneous. Specific mutations have been 
identified in the genes for desmoplakin1, plakoglobin2 and the ryanodine receptor gene3. The 
predominant presenting symptoms are due to ventricular arrhythmias, including palpitations, 
sustained ventricular tachycardia, or uncommonly, sudden cardiac death. Although ARVC/D is 
an unusual disorder, it has been described as the most common cause of sudden death in young 
athletes under the age of 35 in the Veneto area in Italy4 . Heart failure is infrequent but may 
occur due to severe right or biventricular enlargement.                                          
a) Structural Abnormalities and Pathophysiology                                                           
            Anatomically, ARVC/D is characterized by replacement of myocardium with fatty and 
fibrous tissue that primarily affects the epicardium and the mid-myocardium, with relative 
sparing of the endocardium (Figure 1 and 2). This process most commonly affects the posterior 
and inferior areas of the right ventricular inflow tract adjacent to the tricuspid valve5, but it also 
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affects the anterior infundibulum and the apex, thus forming what is known as the "triangle of 
dysplasia"6. Loss of myocardium may result in aneurysm formation, commonly in the basal 
inferior wall, underneath the tricuspid valve7. Fibro-fatty replacement occurs in a segmental, 
patchy fashion and adjacent areas, particularly, the septum, are generally spared. Therefore, 
endomyocardial biopsies, which usually are performed from septal tissue, may be non-
diagnostic. ARVC/D is distinguished from Uhl's anomaly, a congenital disorder in which right 
ventricular myocardium is absent, resulting in a paper-thin right ventricular wall8,9. Recently, 
apoptotic cells have been reported in endomyocardial biopsy specimens10,11,12,13. It is unknown 
how the apoptotic pathway may be initiated in ARVC/D, but may relate to altered intracellular 
calcium concentration1. Inflammatory infiltrates consisting of lymphocytes may also be found 
on biopsy specimens, suggestive of a focal myocarditis, and may explain sporadic cases of 
ARVD/C. 
Figure   1:  In   ARVC/D   there   is 
progressive fibro-fatty replacement of 
the   myocardium   with   thinning   and 
enlargement of the RV wall. In this 
specimen there is gross fatty infiltration 
seen in a portion of the RV wall.
Figure 2:  Trichrome staining shows 
areas of mature fibrosis (F) and adipose 
tissue (A) within the epicardial (Epi) 
and   mid-myocardial   zones,   with 
remaining small clusters of myocytes 
(Myo)   near   the   endocardial   edge 
(Endo).
            Diffuse hypokinesis or regional wall motion abnormalities of the right ventricle can be 
seen with contrast ventriculography, considered to be the most reliable test to assess structural 
abnormalities. RV angiography should be performed in four views: RAO 30, LAO 60, AP and 
lateral. Affected areas will show hypokinesis, akinesis, or dyskinesis. Wall motion abnormalities 
can also be observed by echocardiography but particular attention must be focussed on imaging 
the basal posterior and inferior walls near the tricuspid valve5,14. MRI is emerging as a useful 
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non-invasive tool to identify morphologic abnormalities such as myocardial fat, right ventricular 
chamber size and shape, and wall motion abnormalities with newer cine techniques. However, 
with conventional MR technology, the identification of myocardial fat was not found to be a 
reliable predictor of the presence of ARVC/D15.  Diffuse hypokinesis or regional wall motion 
abnormalities of the right ventricle can be seen with contrast ventriculography, considered to be 
the most reliable test to assess structural abnormalities. RV angiography should be performed in 
four views: RAO 30, LAO 60, AP and lateral. Affected areas will show hypokinesis, akinesis, or 
dyskinesis. Wall motion abnormalities can also be observed by echocardiography but particular 
attention must be focussed on imaging the basal posterior and inferior walls near the tricuspid 
valve5,14. MRI is emerging as a useful non-invasive tool to identify morphologic abnormalities 
such as myocardial fat, right ventricular chamber size and shape, and wall motion abnormalities 
with newer cine techniques. However, with conventional MR technology, the identification of 
myocardial fat was not found to be a reliable predictor of the presence of ARVC/D15. 
b) Electrocardiographic Abnormalities                                                                                 
             Electrocardiographic changes include inverted T waves in the right precordial leads 
beyond V1 (Figure 3) in the absence of right bundle branch block16,17. Right ventricular late 
potentials in the form of epsilon waves may be found on the routine 12 lead ECG. If not present 
overtly, they may be identified by recording the ECG at double standard speed (50mm/sec) and 
amplitude (20mm/mV) and utilizing a 40 Hz filter5 (Figure 4) . Evidence of right ventricular 
parietal block is a QRS duration that is longer in the right (leads V1, V2 and V3) than in the left 
(V4, V5, V6) precordial leads. Suggested parameters to verify this include a localized QRS 
duration greater than 110ms in the right precordial leads, or a maximum QRS duration in leads 
V1, V2 or V3 or more than 25ms above the QRS duration in lead V6 in the presence of 
incomplete or complete right bundle branch block18. The signal averaged electrocardiogram is 
often abnormal and supports the diagnosis of ARVC/D, but if normal, does not exclude the 
diagnosis. The sensitivity of the signal averaged electrocardiogram can be improved by using a 
25 Hz high pass filter and paying particular attention to the Z lead19.
Figure 3: This ECG from a patient with ARVC/D shows T wave inversion throughout the 
precordial leads.
c)   Arrhythmias                                                                
            The ventricular arrhythmias generally arise from the right ventricle, and therefore have a 
left branch block morphology. Right ventricular outflow tract tachycardia (RVOT), must be 
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excluded as this diagnosis carries a benign prognosis and is not hereditary5 . RVOT tachycardia 
has a left bundle branch block morphology. The QRS points to the right and inferior (positive in 
leads II, III, AVF and negative in AVL); this morphology can also be seen in ventricular 
tachycardia due to ARVC/D. Patients with ARVC/D may also experience supraventricular 
arrhythmias20 including atrial flutter21,22,23.        
Figure 4: Epsilon waves, representing right ventricular late potentials, can be brought out by 
recording the ECG at double speed (50mm/s), double amplitude (20mm/mV), and a 40 Hz filter. 
Here, epsilon waves are evident as small, notched deflections just after the QRS in lead V1 
(arrows).
d)   Genetics                                                                                              
             Thirty to fifty percent of patients with ARVC/D will have evidence of familial 
disease25,26. The variable clinical expression and course is believed to be at least in part due to 
genetic heterogeneity. Inheritance is autosomal dominant, with the exception of Naxos disease, 
which is autosomal recessive. Linkage analysis in families with ARVD has revealed several loci 
for this disorder on chromosomes 1, 2, 3, 10, 14, and 1726,27,28,29,30,31(see  Table 1). The 
mutation for ARVD8 has been identified in a gene for desmoplakin on chromosome 6, a 
component of desmosomes that are cellular adhesion proteins responsible for cellular binding1. 
This is the first gene identified to cause a major form of the disease, with autosomal dominant 
inheritance. The locus on chromosome 1 leads to a form of ARVC/D that is notable for 
exertional polymorphic, instead of monomorphic, ventricular tachycardia3,32  and has been 
further identified to encode a cardiac ryanodine receptor gene that is responsible for calcium 
release from the sarcoplasmic reticulum. This genetic mutation has also been implicated in 
familial catecholaminergic polymorphic ventricular tachycardia33,34. Naxos disease discovered 
on the Greek island, Naxos, is characterized by palmoplantar keratosis and woolly hair in 
addition to RV dysplasia. Naxos disease has been mapped to chromosome 17 involving a 
mutation in the gene that encodes plakoglobin, a component of desmosomes and adherens 
junctions responsible for maintaining tight adhesions between cells2. Another mutation in the 
gene for desmoplakin that also causes an autosomal recessive syndrome with woolly hair and a 
dilated left ventricle has been reported in patients from Ecuador35. Therefore, ARVD can result 
from a variety of genetic mechanisms, and in particular, appears to be a disorder of proteins 
involved in cellular adhesion and calcium release. 
ARVD types 1 through 8 are inherited as an autosomal dominant condition, while in Naxos 
disease the inheritance is autosomal recessive.  Not all cases of ARVD are inherited since 
mutations may occur sporadically. Nonetheless, because of the genetic basis for this disorder, it 
is recommended that first degree relatives of ARVD patients be screened with an ECG and 
echocardiogram5. Other non-invasive tests to identify affected family members include signal-
averaged ECG, Holter monitor and exercise stress testing. 
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Table 1
ARVC/D Types
Other Contributory Factors                                                                                             
            A large number of ARVC/D patients are noted to be athletes, and sudden cardiac death is 
more likely during exertion4. Athletic activity, possibly through stretch of myocardial fibers or 
elevated catecholamines may accelerate the degeneration of the ventricular myocardium and 
leads to ventricular arrhythmias. Also in support of the importance of other etiologic factors are 
the reports of Coxsackie virus B3 biopsy specimens36, and recently, enterovirus and adenovirus 
by polymerase chain reaction in 7 of 12 specimens from sporadic cases37. This raises the 
possibility that the myocardium in ARVD is particularly vulnerable to inflammatory processes. 
A superimposed myocarditis could result in lymphocytic infiltrates and fibrofatty replacement of 
the myocardium38,39. It is not known whether the detection of viral DNA or RNA indicates that 
right ventricular cardiomyopathy is a result of viral myocarditis or this cardiomyopathy 
predisposes the heart to viral infection. This process may only affect the RV, but can affect both 
ventricles as well. Patients with left ventricular involvement tend to be older and more 
symptomatic from both arrhythmias and heart failure, consistent with the view that the disease is 
progressive40.  
            Since there is no single "gold standard" diagnostic test to reliably verify this condition, a 
combination of diagnostic criteria have been established by the Task Force of the Working 
Group on Myocardial and Pericardial Disease41. Major criteria include demonstration of severe 
wall motion abnormalities, fibrofatty replacement by biopsy, epsilon waves and family history 
of histologically confirmed disease. Minor criteria include milder alterations of ventricular 
function, inverted T waves in the right precordial leads, late potentials, ventricular tachycardia 
with left bundle branch morphology or frequent premature ventricular complexes (>1000 PVCs 
in a 24 hour period), or family history of suspected or clinically diagnosed ARVC/D. A 
diagnosis can then be made if at least two major, 1 major and 2 minor, or 4 minor criteria from 
different categories are fulfilled41.                                                                                 
            A prospective study of the course of disease in 37 affected families with 365 relatives in 
Italy showed that 41% could be diagnosed with certainty to have ARVC/D while in another 11% 
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the diagnosis was uncertain42. Patients were diagnosed mostly during adolescence and early 
adulthood. After a mean follow-up of 8.5 years, an additional 15 subjects developed structural 
abnormalities or ventricular arrhythmias. In an evaluation of relatives of 67 ARVC/D patients in 
the United Kingdom, 28% of patients had relatives that satisfied the Task Force criteria, but 
another 20% had relatives with only minor ECG, echo or Holter abnormalities suggestive of 
early or mild disease43. Thus familial disease may have been present in up to 48% of index 
cases, which is plausible for a disease with autosomal dominant inheritance. It has been 
suggested by these authors that the standard diagnostic criteria should be modified to identify 
ARVC/D in relatives of patients with confirmed disease if they satisfy any one of the following 
abnormalities: i) T-wave inversion in the precordial leads ii) abnormal SAECG iii) ventricular 
tachycardia with left bundle branch morphology during ECG, Holter monitoring or exercise 
testing iv) greater than 200 PVCs in a 24 hour period or v) any mild echocardiographic 
abnormalities such as RV dilatation with preserved LV function42 .                                 
Treatment/Management
            Therapy with beta blockers44, sotalol44 or amiodarone45 may be effective in suppressing 
ventricular arrhythmias and possibly in preventing sudden cardiac death. Implantation of an ICD 
may also be indicated to prevent sudden death. Catheter ablation of ventricular tachycardia may 
be useful in patients with refractory symptoms despite antiarrhythmic therapy. However, 
ventricular arrhythmias may recur from other areas. Patients should also be advised not to 
perform vigorous exercise or engage in competitive sports. Surgical disarticulation of the right 
ventricular free wall from its attachments to the left ventricle and septum can prevent the 
electrical propagation of ventricular arrythmias from the right to the left ventricle46,47. This was 
an effective means to prevent sudden death prior to the availability of the ICD, but resulted in 
severe right ventricular failure. Management of heart failure includes standard medical therapy 
with  consideration of  heart  transplantation  if  severe  ventricular,  especially biventricular, 
dysfunction   is   present.                                                                                
            It is important to emphasize that risk factors for sudden death are not well characterized. 
A history of syncope, right or left ventricular abnormalities seen on radionuclide angiography 
and QRS dispersion greater than 40ms are independent predictors of sudden death48. However, 
the absence of these factors cannot provide absolute assurance that a patient or relative is free of 
risk. The diverse phenotypic expression of ARVC/D is still being appreciated as new genetic 
loci are discovered. Furthermore, the risk of sudden death is probably variable among different 
types of ARVC/D. In Newfoundland, Canada, ARVD5 was reported to cause sudden death in 
44% of affected males, while females had a more benign course with no sudden deaths49. Thus, 
determining   prognosis   is   complicated   by   the   genetic   heterogeneity   of   this   disorder.
            It is unclear how to advise family members of individuals that have died suddenly with 
ARVD.   The   eight-year   actuarial   probability   of   developing   ventricular   arrhythmias   in 
asymptomatic family members with normal echocardiograms was found to be 3%, with no 
sudden deaths50. The potential risks associated with the implantation and long-term management 
of an intracardiac defibrillator in family members with suspected disease but minimal right 
ventricular dysfunction may far outweigh its potential benefits. Counseling of family members 
needs   to   be   individualized.                                                                  
            The Multidisciplinary Study of Right Ventricular Dysplasia is a multicenter study funded 
by the National Institutes of Health and National Heart, Lung, and Blood Institutes that is 
enrolling patients with a recent diagnosis of ARVC/D into a North American registry. A large 
registry of patients is needed to answer important questions related to diagnosis of the disorder, 
in particular in family members, as well as clinical management of affected patients and risk 
stratification for sudden death. This study will also facilitate genetic research to identify other 
specific   mutations   and   their   role   in   the   pathogenesis   of   this   disease51,52.  
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